• Jaguar Health posted total revenue of $20.27 million, up 816% from a year earlier, driven by $19.07 million in license and grant revenue.
• Operating results swung to income of $10.18 million from an operating loss a year earlier, while net loss attributable to common stockholders narrowed to $7.02 million.
• Product revenue fell 45% to $1.2 million, after a January licensing agreement made Future Pak the exclusive U.S. marketer for Mytesi and Canalevia-CA1.
• Sales and marketing expense dropped to about $0.9 million from $2.5 million due to the dissolution of the Jaguar/Napo Sales and Marketing Group, while R&D rose to $3.9 million from $3.7 million on crofelemer powder-formulation work.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-232722), on May 20, 2026, and is solely responsible for the information contained therein.